Relative Mitochondrial Toxicity of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF) (UCLACAREMITO)
In Vitro and in Vivo Studies of the Relative Mitochondrial Toxicity of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF)
Sponsor: Gilead Sciences
Listed as NCT03251144, this PHASE1/PHASE2 trial focuses on Antiviral Drug Adverse Reaction and Antiviral Toxicity and remains completed. Sponsored by Gilead Sciences, it has been updated 12 times since 2019, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE1_PHASE2
-
Jun 2022 — Dec 2022 [monthly]
Completed PHASE1_PHASE2
▶ Show 7 earlier versions
-
Feb 2022 — Jun 2022 [monthly]
Completed PHASE1_PHASE2
Status: Recruiting → Completed
-
May 2021 — Feb 2022 [monthly]
Recruiting PHASE1_PHASE2
Status: Active Not Recruiting → Recruiting
-
Jan 2021 — May 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
May 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
May 2019 — May 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2018 — May 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2017 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Gilead Sciences
- University of California, Los Angeles
For direct contact, visit the study record on ClinicalTrials.gov .